CPX-351 (VYXEOS) for secondary myeloid neoplasms (pediatric/young adult)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-02-04 — Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms: Early-phase clinical trial launched evaluating CPX-351 (VYXEOS) in patients <22 years with secondary myeloid neoplasms — first dedicated pediatric/young adult study of this liposomal daunorubicin+cytarabine formulation in this indication. (novelty: 3)
Open questions
Related
Contributing findings
Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
04-feb-2026
novelty 3
per-area 3
introduces